Literature DB >> 28249170

Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans.

Leonore Wigger1, Céline Cruciani-Guglielmacci2, Anthony Nicolas3, Jessica Denom2, Neïké Fernandez2, Frédéric Fumeron3, Pedro Marques-Vidal4, Alain Ktorza5, Werner Kramer6, Anke Schulte7, Hervé Le Stunff8, Robin Liechti9, Ioannis Xenarios9, Peter Vollenweider4, Gérard Waeber4, Ingo Uphues10, Ronan Roussel3, Christophe Magnan2, Mark Ibberson11, Bernard Thorens12.   

Abstract

Plasma metabolite concentrations reflect the activity of tissue metabolic pathways and their quantitative determination may be informative about pathogenic conditions. We searched for plasma lipid species whose concentrations correlate with various parameters of glucose homeostasis and susceptibility to type 2 diabetes (T2D). Shotgun lipidomic analysis of the plasma of mice from different genetic backgrounds, which develop a pre-diabetic state at different rates when metabolically stressed, led to the identification of a group of sphingolipids correlated with glucose tolerance and insulin secretion. Quantitative analysis of these and closely related lipids in the plasma of individuals from two population-based prospective cohorts revealed that specific long-chain fatty-acid-containing dihydroceramides were significantly elevated in the plasma of individuals who will progress to diabetes up to 9 years before disease onset. These lipids may serve as early biomarkers of, and help identify, metabolic deregulation in the pathogenesis of T2D.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T2D; biomarkers; ceramides; diabetes; dihydroceramides; glucose intolerance; high-fat diet; human; insulin sensitivity; lipidomics; metabolic challenge; mouse; prognostic; prospective cohort

Mesh:

Substances:

Year:  2017        PMID: 28249170     DOI: 10.1016/j.celrep.2017.02.019

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  73 in total

1.  Rare DEGS1 variant significantly alters de novo ceramide synthesis pathway.

Authors:  Nicholas B Blackburn; Laura F Michael; Peter J Meikle; Juan M Peralta; Marian Mosior; Scott McAhren; Hai H Bui; Melissa A Bellinger; Corey Giles; Satish Kumar; Ana C Leandro; Marcio Almeida; Jacquelyn M Weir; Michael C Mahaney; Thomas D Dyer; Laura Almasy; John L VandeBerg; Sarah Williams-Blangero; David C Glahn; Ravindranath Duggirala; Mark Kowala; John Blangero; Joanne E Curran
Journal:  J Lipid Res       Date:  2019-06-21       Impact factor: 5.922

2.  Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease.

Authors:  Annelise M Poss; J Alan Maschek; James E Cox; Benedikt J Hauner; Paul N Hopkins; Steven C Hunt; William L Holland; Scott A Summers; Mary C Playdon
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

3.  Elevated serum ceramides are linked with obesity-associated gut dysbiosis and impaired glucose metabolism.

Authors:  Brandon D Kayser; Edi Prifti; Marie Lhomme; Eugeni Belda; Maria-Carlota Dao; Judith Aron-Wisnewsky; Anatol Kontush; Jean-Daniel Zucker; Salwa W Rizkalla; Isabelle Dugail; Karine Clément
Journal:  Metabolomics       Date:  2019-10-11       Impact factor: 4.290

4.  Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence.

Authors:  Wee Siong Chew; Federico Torta; Shanshan Ji; Hyungwon Choi; Husna Begum; Xueling Sim; Chin Meng Khoo; Eric Yin Hao Khoo; Wei-Yi Ong; Rob M Van Dam; Markus R Wenk; E Shyong Tai; Deron R Herr
Journal:  JCI Insight       Date:  2019-06-04

5.  Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study.

Authors:  Ian J Neeland; Shruti Singh; Darren K McGuire; Gloria L Vega; Thomas Roddy; Dermot F Reilly; Jose Castro-Perez; Julia Kozlitina; Philipp E Scherer
Journal:  Diabetologia       Date:  2018-08-29       Impact factor: 10.122

6.  DES1: A Key Driver of Lipotoxicity in Metabolic Disease.

Authors:  Jeremy T Blitzer; Liping Wang; Scott A Summers
Journal:  DNA Cell Biol       Date:  2020-03-16       Impact factor: 3.311

Review 7.  Understanding the diversity of membrane lipid composition.

Authors:  Takeshi Harayama; Howard Riezman
Journal:  Nat Rev Mol Cell Biol       Date:  2018-02-07       Impact factor: 94.444

Review 8.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Plasma Ceramide Species Are Associated with Diabetes Risk in Participants of the Strong Heart Study.

Authors:  Amanda M Fretts; Paul N Jensen; Andrew Hoofnagle; Barbara McKnight; Barbara V Howard; Jason Umans; Chaoyu Yu; Colleen Sitlani; David S Siscovick; Irena B King; Nona Sotoodehnia; Rozenn N Lemaitre
Journal:  J Nutr       Date:  2020-05-01       Impact factor: 4.798

10.  Targeting a ceramide double bond improves insulin resistance and hepatic steatosis.

Authors:  Bhagirath Chaurasia; Trevor S Tippetts; Rafael Mayoral Monibas; Jinqi Liu; Ying Li; Liping Wang; Joseph L Wilkerson; C Rufus Sweeney; Renato Felipe Pereira; Doris Hissako Sumida; J Alan Maschek; James E Cox; Vincent Kaddai; Graeme Iain Lancaster; Monowarul Mobin Siddique; Annelise Poss; Mackenzie Pearson; Santhosh Satapati; Heather Zhou; David G McLaren; Stephen F Previs; Ying Chen; Ying Qian; Aleksandr Petrov; Margaret Wu; Xiaolan Shen; Jun Yao; Christian N Nunes; Andrew D Howard; Liangsu Wang; Mark D Erion; Jared Rutter; William L Holland; David E Kelley; Scott A Summers
Journal:  Science       Date:  2019-07-04       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.